Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 15/20 | 0.81 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.45 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.45 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16071751 | 0.89 | FGFR4 (1.00) | FGFR4LCKMAPK14FGFR1FGFR2 | |
| SCHEMBL23653236 | 0.89 | FGFR4 (0.74) | FGFR4LCKMAPK14FGFR1FGFR2 | |
| SCHEMBL16072330 | 0.87 | FGFR4 (0.71) | FGFR4LCKMAPK14FGFR1CCNA2 | |
| SCHEMBL23653237 | 0.85 | FGFR4 (0.91) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL6622549 | 0.83 | LCK (0.69) | FGFR4LCKMAPK14FGFR1FGFR2 | |
| SCHEMBL23653026 | 0.80 | FGFR4 (0.63) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL19792896 | 0.80 | FGFR4 (0.81) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL6620907 | 0.79 | LCK (0.68) | FGFR4LCKMAPK14FGFR1FGFR2 | |
| SCHEMBL3977639 | 0.79 | FGFR4 (0.61) | FGFR4LCKMAPK14FGFR1PLK1 | |
| SCHEMBL6620252 | 0.79 | MAPK14 (0.66) | FGFR4LCKMAPK14FGFR1TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | FGFR4 1220/4885LCK 155/4885MAPK14 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.